Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.31 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22732827 | 0.81 | — | — | |
| SCHEMBL24389449 | 0.81 | KDM4E (0.33) | DGAT1SOAT1GRM2 | |
| SCHEMBL22712443 | 0.79 | KDM4E (0.44) | DGAT1SOAT1 | |
| SCHEMBL22732855 | 0.77 | HIF1A (0.32) | — | |
| SCHEMBL29364796 | 0.77 | KDM4E (0.43) | DGAT1SOAT1 | |
| SCHEMBL22712535 | 0.77 | KDM4E (0.43) | DGAT1SOAT1 | |
| SCHEMBL22732833 | 0.75 | KDM4E (0.35) | — | |
| SCHEMBL22732820 | 0.71 | — | — | |
| SCHEMBL22732508 | 0.67 | RAB9A (0.54) | DGAT1 | |
| SCHEMBL22732825 | 0.67 | KIF11 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4289480-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | F. Hoffmann-La Roche AG (CH) | 2023-12-13 | — | — | EP | disclosed |
| US-20220135528-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | GENENTECH, INC. (US AND US TERRITORIES) | 2022-05-05 | — | — | US | disclosed |
| US-11208387-B2 | Macrocyclic broad spectrum antibiotics | GENENTECH, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200377463-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | GENENTECH, INC. | 2020-12-03 | — | — | US | disclosed |
| WO-2020243155-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | GENENTECH, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377463-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, CLPP, PEPD | DGAT1 3250/4885S1PR1 3811/4885SOAT1 3644/4885 |
| US-20220135528-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, CLPP, PEPD | DGAT1 3250/4885S1PR1 3811/4885SOAT1 3644/4885 |
| US-11208387-B2 | Macrocyclic broad spectrum antibiotics | MRPL21, CLPP, PEPD | DGAT1 3250/4885S1PR1 3811/4885SOAT1 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.